<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02000388</url>
  </required_header>
  <id_info>
    <org_study_id>1012-2011-SPRIX</org_study_id>
    <nct_id>NCT02000388</nct_id>
  </id_info>
  <brief_title>Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management of Post-Vasectomy Pain</brief_title>
  <official_title>Efficacy and Safety of Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management Tool for Adult Male Patients With Post-Vasectomy Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Citrus Valley Medical Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Citrus Valley Medical Research, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, tolerability and safety of intranasal ketorolac tromethamine&#xD;
      (SPRIX) as an option for pain management in post vasectomy patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores on the Visual Analog Scale</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Post Vasectomy Pain</condition>
  <arm_group>
    <arm_group_label>Ketorolac tromethamine (SPRIX)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The intervention used will be standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine</intervention_name>
    <arm_group_label>Ketorolac tromethamine (SPRIX)</arm_group_label>
    <other_name>SPRIX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Male Subject must be between the age twenty five (25) years and sixty four (64)&#xD;
&#xD;
          2. Willing and able to provide an informed consent&#xD;
&#xD;
          3. Has made decision to undergo vasectomy&#xD;
&#xD;
          4. Subject is in good general physical condition as assessed by the Principal&#xD;
             Investigator&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Current treatment with or known allergy or sensitivity to all forms of ketorolac&#xD;
             tromethamine , aspirin , other non steroidal anti inflammatory drugs (NSAIDs) or&#xD;
             Ethylenediaminetetraacetic acid (EDTA)&#xD;
&#xD;
          2. Use of narcotics/opiate or medical marijuana within one (1) week prior to the baseline&#xD;
             visit and entire study participation&#xD;
&#xD;
          3. Use of illegal drugs by self reporting&#xD;
&#xD;
          4. History of drug or alcohol abuse within five (5) years of screening visit&#xD;
&#xD;
          5. History of suicide attempt within five (5) years of screening visit&#xD;
&#xD;
          6. A diagnosis of a severe neuro-psychiatric disease&#xD;
&#xD;
          7. Subject who is currently receiving investigational drug(s) or participated in a&#xD;
             clinical trial involving investigational drug(s) within thirty (30) day of the&#xD;
             screening visit&#xD;
&#xD;
          8. Subject with history of any of the following coronary conditions: (chronic stable&#xD;
             angina being currently treated with long acting nitrates, chronic stable angina&#xD;
             require treatment with short acting nitrates with 90 days of visit 1, angina occurring&#xD;
             during sexual intercourse in the last six months, unstable angina within six months of&#xD;
             visit 1&#xD;
&#xD;
          9. Resting, sitting blood pressure (BP) &gt; 160mm Hg in systolic pressure or &gt; 100mm Hg is&#xD;
             diastolic pressure at screening. If a patient is found to have untreated significant&#xD;
             hypertension at screening and antihypertensive treatment is initiated, assessment for&#xD;
             study eligibility should be deferred until BP and antihypertensive medication have&#xD;
             been stable for at least one month. For patients with previously diagnosed&#xD;
             hypertension, antihypertensive medications must be stable for at least one month prior&#xD;
             to screening.&#xD;
&#xD;
         10. Known or suspected cerebrovascular bleeding, hemorrhagic diathesis or incomplete&#xD;
             hemostasis, and those at high risk of bleeding, have history of a bleeding problem or&#xD;
             low platelet count or coagulation disorder or are on therapy that affects homeostasis&#xD;
&#xD;
         11. Active peptic ulcer disease, recent GI bleeding or perforation, or a history of peptic&#xD;
             ulcers or GI bleeding&#xD;
&#xD;
         12. History of asthma, urticaria or other allergic-type reaction after taking aspirin or&#xD;
             other non steroidal inflammatory drugs (NASIDs)&#xD;
&#xD;
         13. Subject over sixty four (64) years of age&#xD;
&#xD;
         14. Subject with any clinically significant renal function or liver abnormality&#xD;
&#xD;
         15. Subject who has history of swelling of face, mouth, tongue, lips, gums, neck, or&#xD;
             throat (angioedema) or with cardiac decompensation or similar conditions&#xD;
&#xD;
         16. Major surgery scheduled within 3 weeks or screening and for entire participation of&#xD;
             study&#xD;
&#xD;
         17. Current exfoliative dermatitis, Stevens-Johnson syndrome or toxic epidermal necrolysis&#xD;
&#xD;
         18. Any condition in the opinion of the investigator that makes the subject unsuitable for&#xD;
             study&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward L Davis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Citrus Valley Medical Research, Inc.</affiliation>
  </overall_official>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2013</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

